One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine |
| |
| Affiliation: | 1. Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Israel;2. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel;3. Institute of Pulmonary Medicine, Tel Aviv Medical Center, Tel Aviv, Israel;4. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;5. Administration Department, Barzilai Medical Center, Ashkelon, Israel;6. Department of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel;7. Department of Medical Laboratories, Barzilai Medical Center, Ashkelon, Israel;8. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;9. School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel;10. Medical Office of Southern District, Ministry of Health, Ashkelon, Israel |
| |
| Abstract: | BackgroundA third dose of the BNT162b2 SARS-CoV-2 vaccine leads to a significant increase in antibody levels, however, concerns regarding the long-term persistence of this response exist. We assessed the humoral response for one year following vaccination.MethodsA prospective study among immunocompetent healthcare workers (HCW) who received three doses of BNT162b2. anti-spike antibody titers were measured at six predefined timepoints, from before the second vaccine dose, and up to one year afterwards, which is 4–6 months after the third dose. HCW with a history of SARS-CoV-2 infection were excluded.ResultsSeventy-six HCW had all the six serological measurements. Antibody titers significantly increased shortly following the third vaccine dose, and while declining, remained higher from all previous measurements for up to six months.ConclusionsA third dose of BNT162b2 leads to a profound humoral response, which remains significantly higher than previous measurements, even after 6 months. |
| |
| Keywords: | COVID-19 SARS-CoV-2 Pfizer-BioNTech vaccine Vaccination Humoral response |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
